Background
Borderline ovarian tumours (BOTs) are characterized by features of malignant tumours without destructive stromal invasion and represent 10–20% of all epithelial ovarian tumours [
1‐
3]. Nearly one-third of BOTs are diagnosed in women aged under 40 years old, for whom fertility preservation should be considered [
4]. Over the past two decades, conservative surgery that preserve the childbearing potential of young patients is becoming the gold standard for the management of BOTs [
1,
5‐
7]. Evidence from a pooled study showed an estimated cumulative pregnancy rate of 55.7% [
8], which increased to 80% after fertility treatment [
6]. Even for women with advanced-stage serous BOTs, the pregnancy rate was 57.1% according to long-term follow-up data [
9]. However, such conservative surgery is associated with high recurrence rate, although most of which are in the borderline form [
8,
10,
11]. Thus, a thorough fertility counselling is urgently needed before proposing conservative surgery [
5].
However, data on the safety of fertility preservation in endometrioid BOTs (EBOTs) are lacking, given its low incidence [
12‐
14]. Previous studies on EBOTs have focused mainly on their pathological descriptions [
13,
15‐
17] and included only brief descriptions of the clinical features, management and follow-up of these patients [
12,
13,
15]. About one-third of patients with EBOT have synchronous endometrial disorders [
13,
15,
17] and concomitant endometriosis [
12,
13,
16‐
18], and half of the patients with EBOTs are nulliparous [
14]. However, the fertility outcomes after conservative surgery in these EBOTs patients are not known.
Thus, the objective of our study was to establish the feasibility of fertility preservation in young women with EBOTs, as well as their oncological and reproductive outcomes. To our knowledge, this report is the first to be specifically dedicated to fertility results following the conservative treatment of EBOTs and is the largest series on patients with EBOTs.
Discussion
Conservative surgery is widely accepted as the first-choice treatment for BOT patients with the desire to bear children, with promising oncological and reproductive outcomes. However, because of the rarity of EBOTs, there is a paucity of data concerning the natural history and prognosis of this condition. To our knowledge, this case series is the largest to focus on EBOTs and, specifically, on the feasibility of fertility preservation in young EBOT women. Although restricted by its retrospective nature, this study has several meaningful findings and unanswered questions that need further exploration.
The first interesting result in the current series is the safety of the conservative treatment of EBOTs. Among 29 women who underwent conservative treatment, five experienced seven relapses. This rate of recurrence seemed to be higher than that of their radical counterpart (17.2% versus 13.3%), but this difference was not significant. Consistent with their serous/mucinous BOT counterparts, the ovary that is preserved during the initial surgery is the most common site of recurrence [
21‐
23] and can be salvaged by surgery exclusively in most patients [
8,
23,
24]. With respect to EBOTs, similar findings were also reported by Snyder et al. [
13] and by Bell & Kurman [
16], where five and 13 patients who were treated conservatively had no relapses during a mean of 48 months and 6.3 years of follow-up, respectively. Recently, Uzan et al. [
12] also reported seven EBOTS with conservative management (5 with USO alone and 2 with unilateral cystectomy), and one invasive recurrence was observed on the same side of the initial adnexectomy. Consequently, in combination with our present series, conservative surgery that preserves fertility potential can be proposed to young EBOT patients with careful follow-up.
Defining the risk factors of recurrence is crucial towards identifying patients who are at high risk. In the current series, we demonstrated that a young age at diagnosis was the only prognostic factor for recurrence. These results are in agreement with those of Uzan et al [
25], who reported that a young age (< 30 years) was the only independent prognostic factor for SBOT recurrence after conservative surgery. Similarly, in a retrospective multicentre study including 950 patients with BOTs, Trillsch et al reported that recurrence was significantly more frequent in patients < 40 years old (19.0% versus 10.1% 5-year recurrence rate,
p < 0.001) [
26]. Furthermore, a retrospective analysis of a French multicentre prospective database demonstrated that BOT patients with recurrence were 11 years younger than those who were recurrence free (32.24 years versus 43.83 years,
p = 0.0009) [
27]. In fact, as demonstrated in our study, patients at a younger age are more likely to receive conservative surgery, which is significantly associated with recurrence risk [
10,
28]. In this series, conservative surgery showed a trend towards relapse, although the trend was not significant (
p = 0.059), which might be due to the small sample size. In contrast to their endometrioid epithelial ovarian cancer counterparts [
29], in EBOT patients, coexisting endometriosis seemed to be associated with a high recurrence risk (
p = 0.071). Thus, combined with a younger age, the role of the hormonal “field effect” in the development of EBOTs needs further exploration. With respect to the traditionally studied prognostic factors [
8,
10,
28,
30], neither advanced stage nor complete staging was found to be associated with the risk of recurrence. Similarly, in the classical systematic review by Uzan et al [
12], the authors found that all but three EBOT cases were stage I disease and suggested that the peritoneal stage could be omitted in obvious early-stage EBOT.
When cystectomy is compared with USO, the finding that ultraconservative treatment (a cystectomy) increases the risk of recurrence is unsurprising. As demonstrated in serous/mucinous BOTs, ultraconservative surgery is an independent prognostic factor for disease recurrence [
8,
10,
11], and unilateral adnexectomy is advisable in cases of mucinous BOTs [
8,
11]. In contrast, in women with bilateral BOTs, bilateral cystectomy has been suggested as this method increases reproductive outcomes without increasing the recurrence rate compared to USO plus contralateral cystectomy [
31]. Fortunately, an EBOT is mainly a unilateral tumour. To date, only five bilateral cases have been reported among 98 EBOT patients [
12,
13,
15,
16]. In addition, in the present series, five bilateral tumours were found. Thus, regarding conservative surgery in this context, unilateral adnexectomy should be proposed rather than cystectomy [
12] in patients with EBOTs. However, for the uncommon bilateral cases, the preservation of a maximally healthy ovary should be discussed before further studies are performed with a larger sample size to provide a definitive conclusion [
25].
Notably, three cases (5.08%) developed six invasive relapses with a median of 18 months for their first recurrences in our series, which seemed higher than the 2.3% incidence of malignant transformations reported in a large multicentre study that included 950 BOTs [
10]. However, whether such invasive relapses were due to fertility-sparing surgery or to the natural history of the tumour was indeterminate. Of our six invasive recurrences, one occurred in the conservative group, and five (two patients) occurred in the radical group. Additionally, as reported by Uzan et al., a 37-year-old woman had suffered an invasive relapse of ovarian endometrioid carcinoma 7 months after the radical treatment of her first borderline recurrence [
12]. Thus, together with our current series, radical therapy that sacrifices the uterus and both ovaries does not seem to reduce the risk of invasive recurrence, even with complete radical staging.
Recently, several pathological features, such as invasive peritoneal implants, micropapillary patterns, advanced stage, and the stromal microinvasion, have been proposed to define “high-risk” SBOTs in which disease is likely to evolve into invasive disease [
6,
7,
24,
30,
32‐
34]. For MBOTs, intraepithelial carcinoma and the use of cystectomy seems to be associated with invasive relapse [
11,
35,
36]. However, for EBOTs, no such data are available. Among our 59 cases, 24 had intraepithelial carcinomas, whereas only one had an aggressive relapse. Meanwhile, none of the three lethal recurrence cases had stromal microinvasion. Similar findings were also reported by Uzan et al. [
12], and a molecular study has demonstrated that EBOTs harbour both KRAS and PIK3CA oncogene mutations [
37]. Thus, with such limited data, these pathological features seem to have no effect on overall survival and do not influence the type of surgical management. Furthermore, as demonstrated by du Bois et al., most invasive relapses occur during the first 2 years [
10], implying that an intensive post-operative follow-up is necessary.
Concerning fertility results, accumulative evidence suggests the use of fertility preservation in BOT patients with fertility desire [
6]. In addition, even for women with advanced-stage serous BOTs, favourable prognoses and satisfying reproductive outcomes have been demonstrated [
9,
21]. However, among 20 EBOT patients who tried to conceive in the current series, only three pregnancies between two women were achieved. This rate is significantly lower than that of the serous/mucinous counterpart, and even patients with early-stage epithelial ovarian cancers treated with fertility-sparing surgery conceived at a rate of 60–80% [
38,
39]. Notably, 70% of our 20 patients developed EIN/EC during their initial surgery or follow-up periods (Fig.
2), resulting in their need to compromise the uterus and their fertility potential. Previous studies have demonstrated that 20–50% of EBOT patients have synchronous endometrial disorders, and a literature review has shown that among 111 EBOT patients with endometrial evaluations, 41.4% developed synchronous endometrial disorders [
14]. Additionally, coexisting endometriosis was found in 40% (
n = 8/20) of the study patients and would also sacrifice their fecundity. Similar findings were also reported by Roth et al. [
17]; among 30 cases of EBOTs, 67% has associated endometriosis. In addition, in the series by Bell & Kurman, of 33 EBOT cases, 12 had endometriosis [
16]. Given the high prevalence of coexisting endometriosis and endometrial disorders among the EBOT cases, and all 28 patients evaluated for steroid hormone status of EBOT were positive in the immunohistochemical analysis (unpublished data). Thus, whether hormone therapy could be offered to these women for long-term management is an issue awaiting further study. In addition, adherences and alterations in ovarian reserve after surgery might also contribute to these poor fertility outcomes.
The ultimate aim of fertility-sparing surgery in patients with BOT is to fulfil their childbearing desire, and it’s increasingly recommended that young BOT patients should accept oncofertility counselling prior surgery [
5]. Recently, techniques in assisted reproductive medicine have advanced, with treatments ranging from routinely utilized embryo cryopreservation to oocyte and ovarian-tissue cryopreservation, which help retain the possibility of pregnancy without impairing oncological outcomes [
40]. In addition, promising results have been demonstrated in terms of the safety and effectiveness of reproductive medical treatments after fertility-sparing treatment for gynaecological cancers [
6,
40]. Additionally, in vitro data have suggested that gonadotrophins and/or high-dose oestrogens do not stimulate cultured BOT cell proliferation [
41]. In our current study, only one patient received two cycles of IVF-ET treatment, but the treatments failed. This patient had undergone a right laparoscopic adnexectomy and peritoneal biopsies for EBOT at 24 years of age. Twenty months later, she had developed endometrial hyperplasia without atypia, which was successfully reversed with progestin treatment. Afterward, she underwent two cycles of IVF-ET treatment but failed to achieve an ongoing pregnancy after embryo transfer. Approximately 11 years after her initial surgery, a hysterectomy plus left salpingo-oophorectomy was performed due to a borderline recurrence on her left side. She is currently disease-free 14 months after the second surgery. However, the two patients who eventually became pregnant did not receive any assisted reproductive treatments. Given the small sample size, detailed counselling on potential risks and effects should be provided to patients before IVF-ET is offered. Thus, an extensive oncofertility counselling should be proposed to all young women with BOTs, and fertility counselling should become an integral part of the clinical management of women with BOTs [
5].